ArticleAdvanced functional materials2023
Injectable Shear-Thinning Hydrogels with Sclerosing and Matrix Metalloproteinase Modulatory Properties for the Treatment of Vascular Malformations.
Article in Advanced functional materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- The Current State of Mock Circulatory Loop Applications in Aortic and Cardiovascular Research: A Scoping Review.Biomedicines · 2025Review
- An injectable and dual-crosslinked hydrogel for controlled and permanent vascular embolization.Bioactive materials · 2025Article
- Deep Neural-Assisted Flexible MXene-Ag Composite Strain Sensor with Crack Dual Conductive Network for Human Motion Sensing.Materials (Basel, Switzerland) · 2025Article
- Biomimetic Glycosaminoglycan-Analog Hydrogel for Improved Embolization of Aneurysms: Environment-Selective Swelling.Advanced healthcare materials · 2025Article
- Biomaterials for neuroengineering: applications and challenges.Regenerative biomaterials · 2025Review
- Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel.Materials today. Bio · 2024Article
- Development of an Injectable, ECM-Derivative Embolic for the Treatment of Cerebral Saccular Aneurysms.Biomacromolecules · 2024Article
- Nanobioactive Blood-Derived Shear-Thinning Biomaterial for Tissue Engineering Applications.Applied materials today · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 4 countries.
Funding
Abstract
Sac embolization of abdominal aortic aneurysms (AAAs) remains clinically limited by endoleak recurrences. These recurrences are correlated with recanalization due to the presence of endothelial lining and matrix metalloproteinases (MMPs)-mediated aneurysm progression. This study incorporated doxycycline (DOX), a well-known sclerosant and MMPs inhibitor, into a shear-thinning biomaterial (STB)-based vascular embolizing hydrogel. The addition of DOX was expected to improve embolizing efficacy while preventing endoleaks by inhibiting MMP activity and promoting endothelial removal. The results showed that STBs containing 4.5% w/w silicate nanoplatelet and 0.3% w/v of DOX were injectable and had a 2-fold increase in storage modulus compared to those without DOX. STB-DOX hydrogels also reduced clotting time by 33% compared to untreated blood. The burst release of DOX from the hydrogels showed sclerosing effects after 6 h in an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.